4.7 Article

Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models

Journal

CELL DEATH & DISEASE
Volume 12, Issue 7, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41419-021-03924-0

Keywords

-

Categories

Funding

  1. Australian National Health and Medical Research Council [1006592, 1045549, 1065626, APP1145977]
  2. Australian Center for HIV and Hepatitis Virology-ACH2 [PG-002-2016]
  3. Melbourne Health [PG-002-2016]
  4. Sylvia AMP
  5. Charles Viertel Senior Medical Research Fellowship
  6. Royal Melbourne Hospital Keir Fellowship
  7. Australian Government NHMRC
  8. Victorian State Government Operational Infrastructure Support
  9. National Health and Medical Research Council of Australia [1065626] Funding Source: NHMRC

Ask authors/readers for more resources

This study demonstrated a clinically viable strategy for potentially eliminating chronic HBV reservoirs in patients by using orally administered drugs that antagonize the function of cellular inhibitor of apoptosis proteins. The research established a reservoir similar to cccDNA in immunocompetent mice using linearized single genome length HBV DNA and confirmed the clinical relevance of the results using primary human liver organoid models.
A major unmet clinical need is a therapeutic capable of removing hepatitis B virus (HBV) genome from the liver of infected individuals to reduce their risk of developing liver cancer. A strategy to deliver such a therapy could utilize the ability to target and promote apoptosis of infected hepatocytes. Presently there is no clinically relevant strategy that has been shown to effectively remove persistent episomal covalently closed circular HBV DNA (cccDNA) from the nucleus of hepatocytes. We used linearized single genome length HBV DNA of various genotypes to establish a cccDNA-like reservoir in immunocompetent mice and showed that clinical-stage orally administered drugs that antagonize the function of cellular inhibitor of apoptosis proteins can eliminate HBV replication and episomal HBV genome in the liver. Primary human liver organoid models were used to confirm the clinical relevance of these results. This study underscores a clinically tenable strategy for the potential elimination of chronic HBV reservoirs in patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available